Home > Press > Hana Biosciences Announces Conference Call On Second Quarter 2007 Financial Results and Business Update
Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, will announce its 2007 second quarter results on Monday, August 6, 2007, after the close of the financial markets.
Hana Biosciences Announces Conference Call On Second Quarter 2007 Financial Results and Business Update
SOUTH SAN FRANCISCO, CA | Posted on July 25th, 2007
Following the announcement, Hana Biosciences' management will host a live webcast to include a discussion of earnings and a business update at 5:00pm EDT, 2:00pm PDT. Those interested in hearing management's discussion may join the call by dialing (877) 407-8031 in the U.S./Canada. International participants may access the call by dialing (201) 689-8031. Participants may also access a live webcast of the conference call Hana's website at http://www.hanabiosciences.com .
The business update will focus on our drug candidates utilizing our Optisome(tm) Nanoparticle Technology: Marqibo(r) (vincristine sulfate injection), Alocrest(tm) (vinorelbine tartrate injection), and Topotecan hydrochloride injection. Hana will also provide a brief update on the remainder of its product pipeline including Zensana(tm) (ondansetron HCI) Oral Spray.
A replay of this call will be available for one month by dialing (877) 660-6853 U.S./Canada and (201) 612-7415 for International participants. When prompted, enter Account Number #286 and Conference ID #249279. The webcast will be available via the company's website.
About Hana Biosciences
Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at http://www.hanabiosciences.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include without limitation, statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings and commercialization efforts of Hana's product candidates, including its Marqibo product candidate. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its other product candidates will be successful, that Hana will be able to obtain regulatory approval of any of its product candidates, and that the results of clinical trials will support Hana's claims or beliefs concerning the effectiveness of its product candidates. Additional risks that may affect such forward-looking statements include Hana's need to raise additional capital to fund its product development programs to completion, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.
For more information, please click here
Hana Biosciences, Inc.
Investor & Media Contacts:
Remy Bernarda, Director, Investor Relations
Copyright © PrimeNewswire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014
PAM-XIAMEN Offers UV LED wafer April 15th, 2014
Nanocrystalline cellulose modified into an efficient viral inhibitor April 15th, 2014
Targeting cancer with a triple threat: MIT chemists design nanoparticles that can deliver three cancer drugs at a time April 15th, 2014
Relieving electric vehicle range anxiety with improved batteries: Lithium-sulfur batteries last longer with nanomaterial-packed cathode April 16th, 2014
Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014
Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014
Malvern reports on the publication of the 1000th peer-reviewed paper to cite NanoSight’s Nanoparticle Tracking Analysis, NTA April 16th, 2014
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Acid folic was used in the production of the nanogel as targeting agent in drug delivery. The nanogel can be used in the treatment of cancer as a stable nanocarrier. Stability of nanocarriers is an important issue in target delivery mechanisms. Most of nanocarriers, due to their March 17th, 2014
Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014
Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014
Engineers develop new materials for hydrogen storage April 15th, 2014
Near-field Nanophotonics Workshop in Boston April 14th, 2014
LetiDays Grenoble to Present Multiple Perspectives on Development, Challenges and Markets for the IoT April 14th, 2014
Iran to Hold 2nd National Conference on Nanotechnology in Power, Energy Industries April 13th, 2014